Skip to main content

Advertisement

SpringerLink
Log in

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

  • Review
  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

The time to deterioration (TTD) approach has been proposed as a modality of longitudinal analysis of patient-reported outcomes (PROs) in cancer randomized clinical trials (RCTs). The objective of this study was to perform a systematic review of how the TTD approach has been used in phase III RCTs to analyze longitudinal PRO data.

Methods

A systematic literature search was conducted in PubMed/MEDLINE, the Cochrane Library and through manual search to identify studies published between January 2014 and June 2018. All phase III cancer RCTs including a PRO endpoint using the TTD approach were considered. We collected general information about the study, PRO assessment and the TTD approach, such as the event definition, the choice of reference score and whether the deterioration was definitive or not.

Results

A total of 1549 articles were screened, and 39 studies were finally identified as relevant according to predefined criteria. Among these 39 studies, 36 (92.3%) were in advanced and/or metastatic cancer. Several different deterioration definitions were used in RCTs, 10 studies (25.6%) defined the deterioration as “definitive”, corresponding to a deterioration maintained over time until the last PRO assessment available for each patient. The baseline score was explicitly stated as the reference score to qualify the deterioration for most studies (n = 31, 79.5%).

Conclusion

This review highlights the lack of standardization of the TTD approach for the analysis of PRO data in RCTs. Special attention should be paid to the definition of “deterioration”, and this should be based on the specific cancer setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Efficace, F., Fayers, P., Pusic, A., Cemal, Y., Yanagawa, J., Jacobs, M., et al. (2015). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer,121(18), 3335–3342. https://doi.org/10.1002/cncr.29489.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Secord, A. A., Coleman, R. L., Havrilesky, L. J., Abernethy, A. P., Samsa, G. P., & Cella, D. (2015). Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews. Clinical Oncology,12(6), 358–370. https://doi.org/10.1038/nrclinonc.2015.29.

    Article  PubMed  Google Scholar 

  3. Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology,34(16), 1953–1956. https://doi.org/10.1200/JCO.2014.56.7974.

    Article  PubMed  Google Scholar 

  4. Cnaan, A., Laird, N. M., & Slasor, P. (1997). Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine,16(20), 2349–2380.

    Article  CAS  Google Scholar 

  5. Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials. London: Chapman and Hall/CRC.

    Book  Google Scholar 

  6. Anota, A., Hamidou, Z., Paget-Bailly, S., Chibaudel, B., Bascoul-Mollevi, C., Auquier, P., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research,24(1), 5–18. https://doi.org/10.1007/s11136-013-0583-6.

    Article  PubMed  Google Scholar 

  7. Bonnetain, F., Dahan, L., Maillard, E., Ychou, M., Mitry, E., Hammel, P., et al. (2010). Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer,46(15), 2753–2762. https://doi.org/10.1016/j.ejca.2010.07.023.

    Article  PubMed  Google Scholar 

  8. Hamidou, Z., Dabakuyo, T. S., Mercier, M., Fraisse, J., Causeret, S., Tixier, H., et al. (2011). Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. The Oncologist,16(10), 1458–1468. https://doi.org/10.1634/theoncologist.2011-0085.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cortes, J., Hudgens, S., Twelves, C., Perez, E. A., Awada, A., Yelle, L., et al. (2015). Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment,154(3), 509–520. https://doi.org/10.1007/s10549-015-3633-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Verma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., et al. (2018). Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2. Breast Cancer Research and Treatment,170(3), 535–545. https://doi.org/10.1007/s10549-018-4769-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mathoulin-Pelissier, S., Gourgou-Bourgade, S., Bonnetain, F., & Kramar, A. (2008). Survival end point reporting in randomized cancer clinical trials: A review of major journals. Journal of Clinical Oncology,26(22), 3721–3726. https://doi.org/10.1200/JCO.2007.14.1192.

    Article  PubMed  Google Scholar 

  12. Higgins, J., & Green, S. (2014). Cochrane handbook for systematic reviews of interventions Version 5.1. 0 [updated March 2011]. 2011. The Cochrane Collaboration.

  13. Al-Batran, S. E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., et al. (2016). Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology,27(4), 673–679. https://doi.org/10.1093/annonc/mdv625.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bang, Y.-J., Xu, R.-H., Chin, K., Lee, K.-W., Park, S. H., Rha, S. Y., et al. (2017). Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology,18(12), 1637–1651. https://doi.org/10.1016/S1470-2045(17)30682-4.

    Article  CAS  PubMed  Google Scholar 

  15. Bascoul-Mollevi, C., Gourgou, S., Galais, M. P., Raoul, J. L., Bouche, O., Douillard, J. Y., et al. (2017). Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. European Journal of Cancer,84, 239–249. https://doi.org/10.1016/j.ejca.2017.07.038.

    Article  CAS  PubMed  Google Scholar 

  16. Bodoky, G., Scheulen, M. E., Rivera, F., Jassem, J., Carrato, A., Moiseyenko, V., et al. (2015). Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus cisplatin/5-FU: Secondary end point results from the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer,46(2), 109–117. https://doi.org/10.1007/s12029-014-9680-1.

    Article  CAS  PubMed  Google Scholar 

  17. Boye, M., Wang, X., Srimuninnimit, V., Kang, J. H., Tsai, C.-M., Orlando, M., et al. (2016). First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer: Quality of life results from a randomized phase III trial. Clinical Lung Cancer,17(2), 150–160. https://doi.org/10.1016/j.cllc.2015.12.004.

    Article  CAS  PubMed  Google Scholar 

  18. Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., et al. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial. The Lancet Oncology,18(12), 1600–1609. https://doi.org/10.1016/S1470-2045(17)30690-3.

    Article  CAS  PubMed  Google Scholar 

  19. Cella, D., Escudier, B., Tannir, N. M., Powles, T., Donskov, F., Peltola, K., et al. (2018). Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial. Journal of Clinical Oncology,36(8), 757–764. https://doi.org/10.1200/JCO.2017.75.2170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chi, K. N., Protheroe, A., Rodríguez-Antolín, A., Facchini, G., Suttman, H., Matsubara, N., et al. (2018). Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. The Lancet Oncology,19(2), 194–206. https://doi.org/10.1016/S1470-2045(17)30911-7.

    Article  CAS  PubMed  Google Scholar 

  21. Ellis, P. M., Shepherd, F. A., Millward, M., Perrone, F., Seymour, L., Liu, G., et al. (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): A double-blind, randomised, phase 3 trial. The Lancet Oncology,15(12), 1379–1388. https://doi.org/10.1016/s1470-2045(14)70472-3.

    Article  CAS  PubMed  Google Scholar 

  22. Felip, E., Hirsh, V., Popat, S., Cobo, M., Fülöp, A., Dayen, C., et al. (2018). Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced Squamous Cell carcinoma of the lung after first-line platinum-based chemotherapy. Clinical Lung Cancer,19(1), 74–83.e11. https://doi.org/10.1016/j.cllc.2017.06.002.

    Article  CAS  PubMed  Google Scholar 

  23. Fiteni, F., Anota, A., Bonnetain, F., Oster, J.-P., Pichon, E., Wislez, M., et al. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. The European Respiratory Journal,48(3), 861–872. https://doi.org/10.1183/13993003.01695-2015.

    Article  PubMed  Google Scholar 

  24. Fizazi, K., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D., et al. (2014). Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology,15(10), 1147–1156. https://doi.org/10.1016/S1470-2045(14)70303-1.

    Article  CAS  PubMed  Google Scholar 

  25. Geater, S. L., Xu, C. R., Zhou, C., Hu, C. P., Feng, J., Lu, S., et al. (2015). Symptom and quality of life improvement in LUX-Lung 6: An open-label phase III study of afatinib versus cisplatin/gemcitabine in asian patients with EGFR mutation-positive advanced non-small-cell lung cancer. Journal of Thoracic Oncology,10(6), 883–889. https://doi.org/10.1097/JTO.0000000000000517.

    Article  CAS  PubMed  Google Scholar 

  26. Gill, S., Ko, Y. J., Cripps, C., Beaudoin, A., Dhesy-Thind, S., Zulfiqar, M., et al. (2016). PANCREOX: A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. Journal of Clinical Oncology,34(32), 3914–3920. https://doi.org/10.1200/JCO.2016.68.5776.

    Article  CAS  PubMed  Google Scholar 

  27. Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., Andre, T., et al. (2014). Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology,32(31), 3520–3526. https://doi.org/10.1200/JCO.2013.54.1011.

    Article  CAS  PubMed  Google Scholar 

  28. Hagiwara, Y., Ohashi, Y., Okusaka, T., Ueno, H., Ioka, T., Boku, N., et al. (2017). Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open,2(1), e000151. https://doi.org/10.1136/esmoopen-2016-000151.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hamidou, Z., Chibaudel, B., Hebbar, M., Hug de Larauze, M., André, T., Louvet, C., et al. (2016). Time to definitive health-related quality of life score deterioration in patients with resectable metastatic colorectal cancer treated with FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI: The MIROX randomized phase III trial. PLoS ONE,11(6), e0157067. https://doi.org/10.1371/journal.pone.0157067.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., Andre, F., et al. (2016). Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology,27(6), 1047–1054. https://doi.org/10.1093/annonc/mdw139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., et al. (2017). Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial. The Lancet Oncology,18(8), 1104–1115. https://doi.org/10.1016/S1470-2045(17)30421-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lee, C. K., Novello, S., Rydén, A., Mann, H., & Mok, T. (2018). Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: The AURA3 trial. Journal of Clinical Oncology,36(18), 1853–1860. https://doi.org/10.1200/JCO.2017.77.2293.

    Article  CAS  PubMed  Google Scholar 

  33. Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., et al. (2016). Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: Results from the phase III CheckMate 066 study. Annals of Oncology,27(10), 1940–1946. https://doi.org/10.1093/annonc/mdw265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Loriot, Y., Miller, K., Sternberg, C. N., Fizazi, K., De Bono, J. S., Chowdhury, S., et al. (2015). Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. The Lancet Oncology,16(5), 509–521. https://doi.org/10.1016/S1470-2045(15)70113-0.

    Article  CAS  PubMed  Google Scholar 

  35. Machiels, J.-P. H., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Vermorken, J. B., et al. (2015). Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. The Lancet Oncology,16(5), 583–594. https://doi.org/10.1016/S1470-2045(15)70124-5.

    Article  CAS  PubMed  Google Scholar 

  36. Taphoorn, M. J., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S., et al. (2018). Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: A secondary analysis of a randomized clinical trial. JAMA Oncology,4(4), 495–504. https://doi.org/10.1001/jamaoncol.2017.5082.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Novello, S., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., et al. (2015). Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. European Journal of Cancer,51(3), 317–326. https://doi.org/10.1016/j.ejca.2014.11.015.

    Article  CAS  PubMed  Google Scholar 

  38. Pavel, M. E., Singh, S., Strosberg, J. R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M. P., et al. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology,18(10), 1411–1422. https://doi.org/10.1016/S1470-2045(17)30471-0.

    Article  CAS  PubMed  Google Scholar 

  39. Perol, M., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., et al. (2016). Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer,93, 95–103. https://doi.org/10.1016/j.lungcan.2016.01.007.

    Article  PubMed  Google Scholar 

  40. Petrella, T. M., Robert, C., Richtig, E., Miller, W. H., Jr., Masucci, G. V., Walpole, E., et al. (2017). Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer,86, 115–124. https://doi.org/10.1016/j.ejca.2017.08.032.

    Article  CAS  PubMed  Google Scholar 

  41. Qin, S., Bi, F., Jin, J., Cheng, Y., Guo, J., Ren, X., et al. (2015). Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: Results from a randomized registrational study. OncoTargets and Therapy,8, 1363–1373. https://doi.org/10.2147/OTT.S83302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Reck, M., Taylor, F., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H., et al. (2018). Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study. Journal of Thoracic Oncology,13(2), 194–204. https://doi.org/10.1016/j.jtho.2017.10.029.

    Article  CAS  PubMed  Google Scholar 

  43. Saad, F., Fizazi, K., Jinga, V., Efstathiou, E., Fong, P. C., Hart, L. L., et al. (2015). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): A double-blind, multicentre, phase 3, randomised, placebo-controlled trial. The Lancet Oncology,16(3), 338–348. https://doi.org/10.1016/S1470-2045(15)70027-6.

    Article  CAS  PubMed  Google Scholar 

  44. Satoh, T., Bang, Y.-J., Gotovkin, E. A., Hamamoto, Y., Kang, Y.-K., Moiseyenko, V. M., et al. (2014). Quality of life in the trastuzumab for gastric cancer trial. The Oncologist,19(7), 712–719. https://doi.org/10.1634/theoncologist.2014-0058.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Shiroiwa, T., Fukuda, T., Shimozuma, K., Mouri, M., Hagiwara, Y., Doihara, H., et al. (2017). Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: Comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Quality of Life Research,26(2), 445–453. https://doi.org/10.1007/s11136-016-1388-1.

    Article  CAS  PubMed  Google Scholar 

  46. Taphoorn, M. J., Henriksson, R., Bottomley, A., Cloughesy, T., Wick, W., Mason, W. P., et al. (2015). Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. Journal of Clinical Oncology,33(19), 2166–2175. https://doi.org/10.1200/JCO.2014.60.3217.

    Article  CAS  PubMed  Google Scholar 

  47. Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., et al. (2018). Health-related quality-of-life analysis from KEYNOTE-045: A phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. Journal of Clinical Oncology,36(16), 1579–1587. https://doi.org/10.1200/JCO.2017.76.9562.

    Article  CAS  PubMed  Google Scholar 

  48. Vinik, A., Bottomley, A., Korytowsky, B., Bang, Y.-J., Raoul, J.-L., Valle, J. W., et al. (2016). Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: Results from an international phase III trial. Targeted Oncology,11(6), 815–824. https://doi.org/10.1007/s11523-016-0462-5.

    Article  PubMed  Google Scholar 

  49. Yang, Y.-P., Ma, Y.-X., Huang, Y., Zhao, Y.-Y., Fang, W.-F., Hong, S.-D., et al. (2015). QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports,5, 11934. https://doi.org/10.1038/srep11934.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Fiteni, F., Westeel, V., Pivot, X., Borg, C., Vernerey, D., & Bonnetain, F. (2014). Endpoints in cancer clinical trials. Journal of Visceral Surgery,151(1), 17–22.

    Article  CAS  Google Scholar 

  51. Montori, V. M., Permanyer-Miralda, G., Ferreira-González, I., Busse, J. W., Pacheco-Huergo, V., Bryant, D., et al. (2005). Validity of composite end points in clinical trials. BMJ (Clinical Research ed.),330(7491), 594–596. https://doi.org/10.1136/bmj.330.7491.594.

    Article  Google Scholar 

  52. Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003). Composite outcomes in randomized trials: Greater precision but with greater uncertainty? JAMA,289(19), 2554–2559. https://doi.org/10.1001/jama.289.19.2554.

    Article  PubMed  Google Scholar 

  53. Anota, A., Savina, M., Bascoul-Mollevi, C., & Bonnetain, F. (2017). Qolr: An r package for the longitudinal analysis of health-related quality of life in oncology. Journal of Statistical Software, Articles,77(12), 1–30.

    Google Scholar 

  54. Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: A start in setting international standards. The Lancet Oncology,17(11), e510–e514. https://doi.org/10.1016/S1470-2045(16)30510-1.

    Article  PubMed  Google Scholar 

  55. Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et al. (2007). Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology,25(22), 3210–3216. https://doi.org/10.1200/JCO.2006.08.3956.

    Article  CAS  PubMed  Google Scholar 

  56. Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B., & Schrag, D. (2007). When you look matters: The effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute,99(6), 428–432. https://doi.org/10.1093/jnci/djk091.

    Article  PubMed  Google Scholar 

  57. Kiebert, G. M., Curran, D., & Aaronson, N. K. (1998). Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer. Statistics in Medicine,17(5–7), 561–569.

    Article  CAS  Google Scholar 

  58. Fiteni, F., Pam, A., Anota, A., Vernerey, D., Paget-Bailly, S., Westeel, V., et al. (2015). Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. Expert Review of Anticancer Therapy,15(8), 885–891.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the “Institut National du Cancer (INCA 11862)”. The authors thank François Calais (University of Franche-Comté, Besançon, France) for developing and executing the search strategy. The authors thank Fiona Ecarnot (EA3920, University Hospital Besançon, University of Franche-Comté, Besançon, France) for editorial assistance.

Funding

This work was funded by the “Institut National du Cancer (Grant INCA 11862)”.

Author information

Authors and Affiliations

  1. Methodology and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital of Besançon, 3 Boulevard Fleming, 25030, Besançon, France

    E. Charton, F. Bonnetain & A. Anota

  2. University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France

    E. Charton, F. Bonnetain, M.-C. Woronoff-Lemsi & A. Anota

  3. Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France

    B. Cuer, C. Touraine, F. Fiteni & C. Bascoul-Mollevi

  4. Institute of Cancer Research of Montpellier (IRCM), ICM, INSERM, Montpellier, France

    B. Cuer & C. Bascoul-Mollevi

  5. Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy

    F. Cottone & F. Efficace

  6. EA3279 Self-perceived Health Assessment Research Unit, Aix-Marseille University, Marseille, France

    Z. Hamidou

  7. French National Platform Quality of Life and Cancer, Besançon, France

    Z. Hamidou, F. Bonnetain, C. Bascoul-Mollevi & A. Anota

  8. Department of Medical Oncology, University Hospital of Nîmes, Nîmes, France

    F. Fiteni

  9. Department of Clinical Research and Innovation, University Hospital of Besançon, Besançon, France

    M.-C. Woronoff-Lemsi

Authors
  1. E. Charton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Cuer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Cottone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Efficace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Touraine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z. Hamidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Fiteni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Bonnetain
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M.-C. Woronoff-Lemsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Bascoul-Mollevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Anota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Charton.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 38 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Charton, E., Cuer, B., Cottone, F. et al. Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Qual Life Res 29, 867–878 (2020). https://doi.org/10.1007/s11136-019-02367-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-019-02367-7

Keywords

Search

Navigation